Joe Biden (Credit: Doug Mills/The New York Times/Bloomberg via Getty Images)

Biden wants a re­view of the API sup­ply chain. Will that par­lay in­to an ef­fort to 'on­shore' drug man­u­fac­tur­ing?

When for­mer Pres­i­dent Don­ald J. Trump was vot­ed out of of­fice Nov. 2, his gung-ho ef­fort to “on­shore” drug man­u­fac­tur­ing was left most­ly up in the air. Joe Biden has been most­ly mum on whether he would con­tin­ue that ef­fort, but a new ex­ec­u­tive or­der could pro­vide a clue — at least in a few months.

In an or­der signed Wednes­day, Biden de­mand­ed a 100-day gov­ern­men­tal re­view of key sup­ply chains, in­clud­ing for ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (API) used in Amer­i­can drugs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.